These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 39370035)

  • 1. FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia.
    Msika A; Mathias V; Boudigou M; Chambon M; Dubois V; Hajri T; Lotz JP; Massardier J; Descargues P; Gladieff L; Joly F; Lebreton C; Maucort-Boulch D; Bin S; Rousset P; Allias F; Gaillot-Durand L; Devouassoux-Shisheboran M; Lemaitre N; Alfaidy N; Langlois-Jacques C; Alves-Ferreira M; Golfier F; You B; Thaunat O; Bolze PA; Koenig A
    Am J Obstet Gynecol; 2024 Oct; ():. PubMed ID: 39370035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Evidence on Immunotherapy for Gestational Trophoblastic Neoplasia (GTN).
    Mangili G; Sabetta G; Cioffi R; Rabaiotti E; Candotti G; Pella F; Candiani M; Bergamini A
    Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer.
    Stein A; Simnica D; Schultheiß C; Scholz R; Tintelnot J; Gökkurt E; von Wenserski L; Willscher E; Paschold L; Sauer M; Lorenzen S; Riera-Knorrenschild J; Depenbusch R; Ettrich TJ; Dörfel S; Al-Batran SE; Karthaus M; Pelzer U; Waberer L; Hinke A; Bauer M; Massa C; Seliger B; Wickenhauser C; Bokemeyer C; Hegewisch-Becker S; Binder M
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34315821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial.
    You B; Bolze PA; Lotz JP; Massardier J; Gladieff L; Joly F; Hajri T; Maucort-Boulch D; Bin S; Rousset P; Devouassoux-Shisheboran M; Roux A; Alves-Ferreira M; Grazziotin-Soares D; Langlois-Jacques C; Mercier C; Villeneuve L; Freyer G; Golfier F
    J Clin Oncol; 2020 Sep; 38(27):3129-3137. PubMed ID: 32716740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
    Juliá EP; Amante A; Pampena MB; Mordoh J; Levy EM
    Front Immunol; 2018; 9():2140. PubMed ID: 30294328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
    Boyerinas B; Jochems C; Fantini M; Heery CR; Gulley JL; Tsang KY; Schlom J
    Cancer Immunol Res; 2015 Oct; 3(10):1148-1157. PubMed ID: 26014098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody.
    Jochems C; Hodge JW; Fantini M; Tsang KY; Vandeveer AJ; Gulley JL; Schlom J
    Int J Cancer; 2017 Aug; 141(3):583-593. PubMed ID: 28477372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
    Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 in gestational trophoblastic disease: an antibody evaluation.
    Hoeijmakers YM; Simons M; Bulten J; Gorris MAJ; Ottevanger PB; de Vries IJM; Sweep FCGJ
    Acta Obstet Gynecol Scand; 2022 Sep; 101(9):1007-1016. PubMed ID: 35689468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.
    Fujii R; Friedman ER; Richards J; Tsang KY; Heery CR; Schlom J; Hodge JW
    Oncotarget; 2016 Jun; 7(23):33498-511. PubMed ID: 27172898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.
    Giles AJ; Hao S; Padget M; Song H; Zhang W; Lynes J; Sanchez V; Liu Y; Jung J; Cao X; Fujii R; Jensen R; Gillespie D; Schlom J; Gilbert MR; Nduom EK; Yang C; Lee JH; Soon-Shiong P; Hodge JW; Park DM
    JCI Insight; 2019 Oct; 4(20):. PubMed ID: 31536478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: Cohort B of the TROPHIMMUN phase 2 trial.
    You B; Bolze PA; Lotz JP; Massardier J; Gladieff L; Floquet A; Hajri T; Descargues P; Langlois-Jacques C; Bin S; Villeneuve L; Roux A; Alves-Ferreira M; Grazziotin-Soares D; Dherret G; Gerentet C; Rousset P; Freyer G; Golfier F
    Gynecol Oncol; 2023 Jan; 168():62-67. PubMed ID: 36401942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant Mesothelioma Effusions Are Infiltrated by CD3
    Khanna S; Thomas A; Abate-Daga D; Zhang J; Morrow B; Steinberg SM; Orlandi A; Ferroni P; Schlom J; Guadagni F; Hassan R
    J Thorac Oncol; 2016 Nov; 11(11):1993-2005. PubMed ID: 27544053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.
    Donahue RN; Lepone LM; Grenga I; Jochems C; Fantini M; Madan RA; Heery CR; Gulley JL; Schlom J
    J Immunother Cancer; 2017; 5():20. PubMed ID: 28239472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.
    Hicks KC; Fantini M; Donahue RN; Schwab A; Knudson KM; Tritsch SR; Jochems C; Clavijo PE; Allen CT; Hodge JW; Tsang KY; Schlom J; Gameiro SR
    Oncoimmunology; 2018; 7(11):e1466018. PubMed ID: 30377559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-dependent cell-mediated cytotoxicity using T cells with NK-like phenotype in combination with avelumab, an anti-PD-L1 antibody.
    Liu D; Hu Y; Wei J; Zhang W; Piao C; Lu Y; Wang Y; Liu J; Lu X
    Immunology; 2022 Oct; 167(2):212-220. PubMed ID: 35751879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.
    Grenga I; Donahue RN; Gargulak ML; Lepone LM; Roselli M; Bilusic M; Schlom J
    Urol Oncol; 2018 Mar; 36(3):93.e1-93.e11. PubMed ID: 29103968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.
    Della Corte CM; Fasano M; Ciaramella V; Cimmino F; Cardnell R; Gay CM; Ramkumar K; Diao L; Di Liello R; Viscardi G; Famiglietti V; Ciardiello D; Martini G; Napolitano S; Tuccillo C; Troiani T; Martinelli E; Wang J; Byers L; Morgillo F; Ciardiello F
    J Exp Clin Cancer Res; 2022 Mar; 41(1):109. PubMed ID: 35346313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study.
    Braga A; Paiva G; Ghorani E; Freitas F; Velarde LGC; Kaur B; Unsworth N; Lozano-Kuehne J; Dos Santos Esteves APV; Rezende Filho J; Amim J; Aguiar X; Sarwar N; Elias KM; Horowitz NS; Berkowitz RS; Seckl MJ
    Lancet Oncol; 2021 Aug; 22(8):1188-1198. PubMed ID: 34181884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct microRNA profiles for complete hydatidiform moles at risk of malignant progression.
    Lin LH; Maestá I; St Laurent JD; Hasselblatt KT; Horowitz NS; Goldstein DP; Quade BJ; Sun SY; Braga A; Fisher RA; Berkowitz RS; Elias KM
    Am J Obstet Gynecol; 2021 Apr; 224(4):372.e1-372.e30. PubMed ID: 33031755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.